Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Tango Therapeutics (TNGX) is anticipated to report a Q2 2025 loss of $0.35 per share, a 45.8% year-over-year decline, on revenues projected to fall 68.9% to $6.19 million. Despite this consensus outlook, the company's positive Zacks Earnings ESP of +0.57% and a Zacks Rank #2 strongly suggest TNGX is likely to exceed consensus EPS estimates when it reports on August 5, potentially driving stock appreciation.

Analysis

Tango Therapeutics (TNGX) presents a dichotomous outlook ahead of its Q2 2025 earnings report scheduled for August 5. The consensus forecast points to a significant year-over-year deterioration in fundamentals, with revenues expected to fall 68.9% to $6.19 million and the loss per share to widen by 45.8% to $0.35. Despite this bearish backdrop, quantitative signals suggest a high probability of a positive earnings surprise. The company's Zacks Rank of #2 (Buy) combined with a positive Earnings ESP (Expected Surprise Prediction) of +0.57% historically predicts an EPS beat nearly 70% of the time. This short-term bullish signal is reinforced by a 1.62% upward revision in the consensus EPS estimate over the last 30 days. However, the company's recent performance history is inconsistent, having beaten EPS estimates in only two of the last four quarters and delivering a -5.88% negative surprise last quarter. The primary tension for investors is whether a potential EPS beat can outweigh the stark reality of a severe revenue contraction, making management's forward-looking guidance on the earnings call a critical determinant for the stock's sustained direction.

Key Decisions for Investors

• Given the strong statistical likelihood of an earnings beat based on the Zacks Rank #2 and positive ESP, traders with a higher risk tolerance could consider a short-term tactical long position leading into the report.
• Long-term investors should remain cautious due to the severe projected declines in revenue and earnings, and must closely analyze management's guidance on the earnings call for signs of a fundamental business turnaround before committing new capital.
• Investors should be prepared for significant volatility, as a narrow EPS beat might not be sufficient to drive the stock higher if it is accompanied by weak revenue figures or a conservative outlook.